Cytokinetics, Inc. (NASDAQ: CYTK) reported Q1 EPS of ($0.27), $0.07 better than the analyst estimate of ($0.34). Revenue for the quarter came in at $8 million versus the consensus estimate of $7.69 million.

For earnings history and earnings-related data on Cytokinetics, Inc. (CYTK) click here.